C4 Therapeutics Inc. has entered into a license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins.

Dyadic International Inc.'s Dutch subsidiary, Dyadic Nederland BV, has entered into a strategic partnership agreement and collaboration with Rabian BV to develop efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.

Max Biopharma Inc. and Metaba LLC are collaborating to study the effects of oxysterol drug candidates that target metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis or NASH), idiopathic pulmonary fibrosis, chronic inflammation, and atherosclerosis on metabolic processes.

Abbvie Inc. and Tentarix Biotherapeutics Inc. have established a multiyear collaboration focused on the discovery and development of conditionally active, multispecific biologic candidates against one target in oncology and another in immunology.

Using its proprietary AI-Immunology platform, Evaxion has identified novel vaccine targets against a bacterial pathogen causing severe health issues.

Xyphos Biosciences Inc., a wholly owned subsidiary of Astellas Pharma Inc., and Kelonia Therapeutics Inc. have entered into a research collaboration and license agreement to develop novel immuno-oncology therapeutics.

Intellia Therapeutics Inc. and Recode Therapeutics Inc. have established a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis.

Vantai Inc. and Bristol Myers Squibb Co. have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.